[Transition of renal function after repeated intraperitoneal CDDP administration].
The purpose of this study was to clarify the development of renal dysfunction in 20 patients intraperitoneally administered CDDP after gastrectomy and to determine whether this treatment is tolerable for outpatients. The initial dose of CDDP was 100 mg/body and the successive dose was 40-50 mg/body. Subjects received 96 intraperitoneal CDDP administrations in all, and their total doses ranged 90-400 mg (median: 249 mg). As a result, renal dysfunction up to grade 2 developed in 7 patients (35%) with high frequency, while the rate to all administrations was 12% (12/96). Although the creatinine clearance decreased with the increase of cumulative dose, serum creatinine or BUN did not relate to this change. Therefore, we concluded that this treatment for outpatients could not be recommended because there was nothing to indicate renal function easily or sensitively at the present time.
Arai
K
K
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Kitamura
M
M
Iwasaki
Y
Y
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000601:surgery
D002945:Cisplatin